

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE		Docket No.	Application No.		
Approved for use through 10/31/2002		US Patent and Trademark Office		50623.349	10/693,047		
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Applicant			
				Wouter E. Roorda et al.			
				Filing Date	Group Art Unit		
				October 24, 2003	1615		
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
CA	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	
	A2	4,977,901	12/18/90	Ofstead	128	772	
	A3	5,021,044	6/4/91	Sharkawy	604	53	
	A4	5,268,164	12/7/93	Kozarich et al.	424	9	
	A5	5,328,471	7/12/94	Slepian	604	101	
	A6	5,464,650	11/7/95	Berg et al.	427	2.30	
	A7	5,578,073	11/26/96	Haimovich et al.	623	1	
	A8	5,605,696	2/25/97	Eury et al.	424	423	
	A9	5,628,730	5/13/97	Shapland et al.	604	21	
	A10	5,667,767	9/16/97	Greff et al.	424	9.411	
	A11	5,670,558	9/23/97	Onishi et al.	523	112	
	A12	5,686,416	11/11/97	Kozarich et al.	514	15	
	A13	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A14	5,716,981	2/10/98	Hunter et al.	514	449	
	A15	5,800,392	9/1/98	Racchini	604	96	
	A16	5,824,049	10/20/98	Ragheb et al.	623	1	
	A17	5,830,178	11/3/98	Jones et al.	604	49	
	A18	5,830,879	11/3/98	Isner	514	44	
	A19	5,837,313	11/17/98	Ding et al.	427	2.21	
	A20	5,843,172	12/1/98	Yan	623	1	
	A21	5,851,508	12/22/98	Greff et al.	424	9.411	
	A22	5,865,814	2/2/99	Tuch	604	265	
	A23	5,873,904	2/23/99	Ragheb et al.	623	1	
	A24	5,971,954	10/26/99	Conway et al.	604	96	
	A25	5,980,928	11/9/99	Terry	424	427	
	A26	5,980,972	11/9/99	Ding	427	2.24	
	CA	A27	6,010,530	1/4/00	Goicoechea	623	1

	A28	6,015,541	1/18/00	Greff et al.	424	1.25	
	A29	6,096,070	8/1/00	Ragheb et al.	623	1	
	A30	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	A31	6,165,212	12/26/00	Dereume et al.	623	1.13	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 91/12846	9/5/91	PCT WIPO				
	B2	EP 0 665 023	8/2/95	European				
	B3	WO 97/45105	12/4/97	PCT WIPO				
	B4	WO 99/63981	12/16/99	PCT WIPO				
	B5	EP 0 970 711	1/12/00	European				
	B6	WO 00/12147	3/9/00	PCT WIPO				
	B7	WO 00/64506	11/2/00	PCT WIPO				
	B8	WO 01/01890	1/11/01	PCT WIPO				
	B9	WO 01/45763	6/28/01	PCT WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Alt et al., <i>Inhibition of Neointima Formation After Experimental Coronary Artery Stenting: A New Biodegradable Stent Coating Releasing Heparin and the Prostacyclin Analogue Iloprost</i> , Circulation March 28, 2000; 101:1453-1458.
	C2	Baldus et al., <i>Treatment Of Aortocoronary Vein Graft Lesions With Membrane-Covered Stents</i> , Circulation, 2000; 102:2024-2027.
	C3	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC Vol. 13, No. 2, February 1989:252A (Abstract).
	C4	Christodoulos Stefanadis et al., <i>Stents Covered By Autologous Venous Grafts: Feasibility And Immediate And Long-Term Results</i> , American Heart Journal, March 2000, Vol. 139, No. 3, pp. 437-445.
	C5	de Scheerder et al., <i>Local Methylprednisolone Inhibition Of Foreign Body Response To Coated Intracoronary Stents</i> , Coronary Artery Disease, February 1996, Vol. 7 No. 2, pp. 161-166.
	C6	Forrester, et al., <i>A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies</i> , Journal of the American College of Cardiology, March 1, 1991, Vol. 17, No. 3, pp 758-769.
	C7	Hurni et al., <i>Permeability Enhancement in Caco-2 Cell Monolayers by Sodium Salicylate and Sodium Taurodiethylhydrofusidate: Assessment of Effect-Reversibility and Imaging of Transepithelial Transport Routes by Confocal Laser Scanning Microscopy</i> , The Journal of Pharmacology and Experimental Therapeutics Vol. 267, No. 2, pp. 942-950 (1993).
	C8	Kasirajan et al., <i>Delayed onset of ascending paralysis after thoracic aortic stent graft deployment</i> , Journal of Vascular Surgery, Jan. 2000, Vol. 31, No. 1, Part 1, pp. 196-199.
	C9	Matsumaru et al., <i>Emboic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn, Vol. 8, No. 7 (1997), pp. 555-569.
	C10	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6)(1985), pp. 2490-2498.

C11	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol. (1997), pp. 157-162.
C12	Monnier et al., <i>The Use Of The Covered Wallstent For The Palliative Treatment Of Inoperable Tracheobronchial Cancers</i> , Chest, 1996; 110:5:1161-1168.
C13	Nobuyoshi et al., <i>Restenosis After Percutaneous Transluminal Coronary Angioplast: Pathologic Observations in 20 Patients</i> , Journal of the American College of Cardiology, February 1991, Vol. 17, No. 2, pp 433-439.
C14	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal (Dec. 1998), pp. 1081-1087.
C15	Park et al., <i>Anti-inflammatory Stent Coatings: Dexamethasone And Related Compounds</i> , Semin. Intervent. Cardiol. 1998; 3:191-195.
C16	Rechavia et al., <i>Biocompatibility of Polyurethane-Coated Stents: Tissue and Vascular Aspects, Catheterization and Cardiovascular Diagnosis</i> 45:202-207 (1998).
C17	Schellhammer et al., <i>Polyethylene Terephthalate And Polyurethane Coatings For Endovascular Stents: Preliminary Results In Canine Experimental Arteriovenous Fistulas</i> , Radiology, April 1999, pp. 169-175.
C18	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
C19	van Hoogdalem et al., <i>3-Amino-1-hydroxypropylidene-1, 1-diphosphonate (APD): A Novel Enhancer Of Rectal Cefoxitin Absorption In Rats</i> , J. Pharm. Pharmacol. 1989, 41:339-341.
C20	van Hoogdalem et al., <i>Rectal Absorption Enhancement of Cefoxitin and Desglycinamide Arginine Vasopressin by Sodium Tauro-24, 25-Dihydrofusidate in Conscious Rats</i> , The Journal of Pharmacology and Experimental Therapeutics 1989, Vol. 251, No. 2, pp. 741-744.
EXAMINER	DATE CONSIDERED 3/31/04
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	